[Antiplatelet agents and cardiovascular prevention].

The main contributions of meta-analysis methodology to antiplatelet therapy in the field of cardiovascular prevention are presented with regard to the different sectors of the health system: help with therapeutic information, help in the planning of clinical trials for the pharmaceutical industry and help in decision-making for Health Authorities. The results of meta-analysis of available data concerning aspirin in cardio-vascular prevention are discussed, in an attempt to define optimal daily dose and duration of aspirin treatment.